Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 1;8(7):701–710. doi: 10.1242/dmm.020248

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 4. — Reversal of visual dysfunction following daily systemic treatment with MTP-131. Daily MTP-131 treatment is indicated by shading. Dotted lines are traces from Fig. 1, depicting the effects of Veh treatment. (A) Improvement of SF function was present within 2 weeks of treatment in ND+STZ mice [MTP-131 versus Veh; 0.382±0.001 c/d (n=7) versus 0.377 c/d±0.006 (n=12)], within 3 weeks in DD mice [MTP-131 versus Veh: 0.342 c/d±0.001 (n=8) versus 0.347 c/d±0.003 (n=7)] and within 1 week in DD+STZ mice [MTP-131 versus Veh: 0.340±0.001 c/d (n=11) versus 0.313±0.002 c/d (n=6)]. Full restoration of function was achieved by 24 weeks in ND+STZ (n=4) and DD+STZ (n=8) mice, and by 31 weeks in DD mice (n=5). ND (MTP-131) did not differ statistically from ND (Veh) at any age (n=6, P>0.05). (B) Cone- and rod-mediated function was restored by MTP-131 treatment, as measured at 28 weeks of age (P>0.05); dotted lines depict the results of Veh treatment abstracted from Fig. 1. (C-F) MTP-131 restored normal CS in each experimental group by 32 weeks.